US2008090797A1PendingUtilityA1

{Beta}-Lactamyl vasopression V1a antagonists and methods of use

65
Assignee: AZEVAN PHARMACEUTICALS INCPriority: Oct 12, 2001Filed: Oct 17, 2007Published: Apr 17, 2008
Est. expiryOct 12, 2021(expired)· nominal 20-yr term from priority
Inventors:Gary A. KoppelRobert F. Bruns, Jr.
A61P 9/08A61P 43/00A61P 3/10A61P 31/18A61P 7/02A61P 9/10A61P 37/08A61P 37/02A61P 9/04A61P 35/00A61P 37/06A61P 9/00A61P 7/00A61P 25/32A61P 25/36A61P 25/22A61P 25/06A61P 29/00A61P 25/28A61P 25/00A61P 25/08A61P 25/24A61P 25/16A61P 27/02A61P 29/02A61P 25/18A61P 25/04A61P 19/02A61P 1/04A61P 21/00A61P 19/00A61P 1/00A61P 17/00A61P 1/06A61P 17/06A61P 13/10A61P 13/02A61P 15/06A61P 15/00A61P 11/00A61P 19/10A61P 19/04A61P 1/08A61P 11/06A61P 1/02A61P 19/08A61P 11/02A61P 1/12A61P 17/04A61P 13/08C07D 409/14C07D 413/14C07D 413/04C07D 403/04C07D 417/14C07D 401/14C07D 403/14
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V 1a receptor.

Claims

exact text as granted — not AI-modified
1 . A compound of the formula  
       
         
           
           
               
               
           
         
       
       and pharmaceutically acceptable salts, hydrates, and solvates thereof.  
     
     
         2 . A composition comprising a compound of  claim 1  and a pharmaceutically acceptable carrier, diluent, or excipient therefor, or a combination thereof.

Join the waitlist — get patent alerts

Track US2008090797A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.